Picture1.png
Nurix Therapeutics Announces Addition of Dr. Jason Kantor to its Management Team
July 13, 2020 08:00 ET | Nurix
SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Jason Kantor as senior vice...
Picture1.png
Nurix Therapeutics Announces Addition of Immuno-Oncology Clinical Experts to its Management Team
June 16, 2020 08:00 ET | Nurix
SAN FRANCISCO, June 16, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Michael T. Lotze as chief...
Picture1.png
Nurix Therapeutics Closes $120 Million Financing to Advance Targeted Protein Modulation Drug Pipeline
March 12, 2020 08:00 ET | Nurix
SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced it has closed an oversubscribed $120 million...
Picture1.png
Nurix Therapeutics to Present at the Cowen & Co. 40th Annual Health Care Conference
February 27, 2020 08:00 ET | Nurix
SAN FRANCISCO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced that CEO Arthur Sands will present at the Cowen...
Picture1.png
Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies
January 09, 2020 08:00 ET | Nurix
SAN FRANCISCO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company researching novel therapies that control degradation of disease-causing proteins, today announced a global...
Picture1.png
Nurix Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020 08:00 ET | Nurix
SAN FRANCISCO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs announced today that CEO Arthur Sands will present at the 38th...
Picture1.png
Nurix Therapeutics Announces Scientific Presentations on its BTK Program at the 61st American Society of Hematology Annual Meeting
November 18, 2019 08:00 ET | Nurix
SAN FRANCISCO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing novel therapies that control disease-causing proteins, today announced an oral presentation on its...
Picture1.png
Nurix Therapeutics Announces Key Management Additions
November 14, 2019 08:00 ET | Nurix
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced the appointment of Dr. Christine Ring...
Picture1.png
Nurix Therapeutics Announces Upcoming Investor Conference Schedule
November 12, 2019 08:00 ET | Nurix
SAN FRANCISCO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that the Company management team will...
Picture1.png
Nurix Therapeutics Announces Upcoming Scientific Presentation for its CBL-B Program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
October 22, 2019 08:00 ET | Nurix
SAN FRANCISCO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that it will present data on its...